Table 1.

Baseline Characteristics for All Patients With a Shock Event (n=963)

CharacteristicsCount
Age at implant, mean (SD)61.29 (13.65)
Sex, n (%)
 Male778 (80.79)
 Female185 (19.21)
Health plan, n (%)
 Comprehensive/indemnity194 (20.15)
 EPO/PPO516 (53.58)
 POS/POS w/capitation69 (7.17)
 HMO117 (12.15)
 Other/unknown67 (6.96)
Primary insurance, n (%)
 Commercial573 (59.50)
 Medicare390 (40.50)
Preimplant comorbid conditions, n (%)
 Acute myocardial infarction or ischemic heart disease574 (59.61)
 Conduction disorder116 (12.05)
 Chronic kidney disease66 (6.85)
 Arrhythmia (atrial)354 (36.76)
 Arrhythmia (ventricular)394 (40.91)
 Cardiac arrest91 (9.45)
 Arrhythmia (dysrhythmia)170 (17.65)
 Heart failure488 (50.68)
 Cardiomyopathy468 (48.60)
 Valvular heart disease246 (25.55)
 Stroke/transient ischemic attack35 (3.63)
 Congenital heart disease28 (2.91)
 Hypertension329 (34.16)
 CHADS2 score, mean (SD)1.30 (1.07)
Preimplant medication use, n (%)
 Antidiabetic medications160 (16.61)
 β-blockers482 (50.05)
 Oral anticoagulants201 (20.87)
Shock events
 Total shock events, mean (SD)1.96 (1.77)
Device type, n (%)
 VR219 (22.74)
 CRT-D269 (27.93)
 DR475 (49.33)
Shock type, n (%)
 Appropriate shock(s) only416 (43.20)
 Inappropriate shock(s) only403 (41.85)
 Indeterminate shock type(s) only30 (3.11)
 Mixed shock types114 (11.84)
  • CRT-D indicates cardiac resynchronization therapy defibrillator; DR, dual-chamber implantable cardioverter–defibrillator; EPO, exclusive provider organization; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; SD, standard deviation; and VR, single-chamber implantable cardioverter–defibrillator.